Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Resource Profile: VariableDefinition - Examples

Page standards status: Trial-use Maturity Level: 1

Examples for the variable-definition Profile.

OutcomeVariable: Nonfatal myocardial infarction or stroke
OutcomeVariable: Remission of diabetes
OutcomeVariable: New onset depression
OutcomeVariable_Treatment_with_opioids
OutcomeVariable_Additional_GI_surgical_procedure
OutcomeVariable: HbA1c at 12 months
OutcomeVariable: HbA1c at 36 months
OutcomeVariable: HbA1c at 24 months
OutcomeVariable: HbA1c at 60 months
OutcomeVariable: HbA1c at 6 months
ExposureVariable: Age (as continuous variable)
ExposureVariable: Body Mass Index (as continuous variable)
ExposureVariable: pht013093.v1.p1 SUBJECT_ID
ExposureVariable: pht013093.v1.p1 SEX
ExposureVariable: pht013093.v1.p1 RACE
ExposureVariable: pht013093.v1.p1 Age at diagnosis
ExposureVariable: pht013094.v1.p1 SAMPLE_ID
ExposureVariable: pht013094.v1.p1 BODY_SITE
ExposureVariable: pht013094.v1.p1 SAMPLE_USE
ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
ExposureVariable: pht013094.v1.p1 Source_Type
ExposureVariable: pht013094.v1.p1 IS_TUMOR
Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
NHANES SEQN Respondent Sequence Number
NHANES LBXGLU: Fasting Glucose (mg/dL)
NHANES LBDGLUSI: Fasting Glucose (mmol/L)
NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
Median Age of Parachute Intervention Group
Age
Sex
Ethnic Group
Height
History of Broken Bones
History of Acrophobia
History of Parachute Use
Family History of Parachute Use
Frequent Flier
International vs Domestic Flight
Aircraft Type
Velocity
Altitude
Outcome: Death or Major Traumatic Injury on Impact
Outcome: Injury Severity Score on Impact
Outcome: Death or Major Traumatic Injury 30 days after Impact
Outcome: Injury Severity Score 30 days after Impact
Health Survey Score Total
Health Survey Score-Physical Health Subscore
Health Survey Score-Mental Health Subscore
Weight
OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
VariableDefinition: Gender
VariableDefinition: Condition(s)
VariableDefinition: Comparator
VariableDefinition: Unit
VariableDefinition: NTproBNP
VariableDefinition: Date of birth
VariableDefinition: Date of measurement
EvidenceVariable: Time of measurement
Time to integration of results in a recommendation
EvidenceVariable: Patient id
EvidenceVariable: case_id
Change in Mean Systolic Blood Pressure (NCT03640312)
Mean Systolic Blood Pressure (NCT03640312)
Change in Mean Diastolic Blood Pressure (NCT03640312)
Mean Diastolic Blood Pressure (NCT03640312)
Proportion of Patients With Hypertension Control (NCT03640312)
Number of Patients Requiring Step up Treatment (NCT03640312)
Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
Medication Adherence (NCT03640312)
Health-related Quality of Life (NCT03640312)
Change in Mean Systolic Blood Pressure (NCT03640312)
Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
Rate of Adverse Events of Special Interest (NCT03640312)
Mean Change in Serum Potassium (NCT03640312)
Mean Change in Serum Sodium (NCT03640312)
Mean Change in Blood Urea Nitrogen (NCT03640312)
Mean Change in Serum Creatinine (NCT03640312)
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
Systolic blood pressure at 12 weeks
Diastolic blood pressure at 12 weeks
Medication Adherence at 12 weeks
Hypertension Control at 12 weeks
Add-on Amlodipine at 6 weeks
Adverse event free and hypertension control at 12 weeks
OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
OutcomeVariable_All_cause_mortality